Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 5Ovarian Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × taxane × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Morphotek

Phase 3 Terminated
1,100 enrolled 30 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡